BLFS Stock BioLife Solutions (BLFS, $28.32) Stochastic Oscillator left the overbought zone on February 18, 2025

GET DAILY SIGNALS

Get AI intraday signals

BLFS - BioLife Solutions

Stochastic signal

View

Odds of DOWN Trend

Price: $28.32

Daily change: +$0.55 (+1.98%)

Daily volume: 220.5K

Capitalization: $1.3B

Industry: Medical Specialties

BLFS saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for BLFS moved out of overbought territory on February 21, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 62 similar instances where the indicator exited the overbought zone. In of the 62 cases the stock moved lower. This puts the odds of a downward move at .

Technical Analysis (Indicators)

Bearish Trend Analysis

BLFS moved below its 50-day moving average on February 21, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 14, 2025. You may want to consider a long position or call options on BLFS as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BLFS just turned positive on February 18, 2025. Looking at past instances where BLFS's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for BLFS crossed bullishly above the 50-day moving average on February 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLFS advanced for three days, in of 327 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.402) is normal, around the industry mean (23.448). P/E Ratio (238.095) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (15.094) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.461) is also within normal values, averaging (41.230).